NCT05565807View on ClinicalTrials.gov

Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

February 9, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

February 19, 2028

Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
BIOLOGICAL

STI-6129

Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor.

Trial Locations (4)

100000

RECRUITING

Beijing Chao-Yang Hospital，Capital Medicine University, Beijing

100191

RECRUITING

Peking university Third hospital, Beijing

510080

RECRUITING

The first affiliated hospital ,Sun Yat-sen University, Guangzhou

Unknown

RECRUITING

The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Zhejiang ACEA Pharmaceutical Co. Ltd.

INDUSTRY